<DOC>
	<DOCNO>NCT01862367</DOCNO>
	<brief_summary>This study conduct globally . The aim observational study investigate incidence specific adverse drug reaction associate use recombinant factor XIII ( NovoThirteen速 ) patient congenital FXIII A-subunit deficiency ( congenital FXIII deficiency ) , comprise FXIII antibody , allergic reaction , embolic thrombotic event lack therapeutic effect . The study aim observe patient expose NovoThirteen速 EU , additional patient select non-EU country . Recombinant FXIII ( rFXIII ) register EU Switzerland NovoThirteen速 Canada Tretten速 .</brief_summary>
	<brief_title>Use rFXIII Treatment Congenital FXIII Deficiency , Prospective Multi-centre Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Informed consent obtain studyrelated activity . ( Studyrelated activity procedure relate recording data accord protocol ) Able willing provide sign informed consent ( patient 's legally acceptable representative ( LAR ) consent , applicable ) , require local ethic committee , governmental regulatory authority Congenital FXIII Asubunit deficiency Actual plan exposure rFXIII</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>